| Mutations driving CLL and their evolution in progression and relapse DA Landau, E Tausch, AN Taylor-Weiner, C Stewart, JG Reiter, J Bahlo, ... Nature 526 (7574), 525-530, 2015 | 1234 | 2015 |
| Venetoclax and obinutuzumab in patients with CLL and coexisting conditions K Fischer, O Al-Sawaf, J Bahlo, AM Fink, M Tandon, M Dixon, S Robrecht, ... New England Journal of Medicine 380 (23), 2225-2236, 2019 | 972 | 2019 |
| Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial K Fischer, J Bahlo, AM Fink, V Goede, CD Herling, P Cramer, ... Blood, The Journal of the American Society of Hematology 127 (2), 208-215, 2016 | 843 | 2016 |
| Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial S Stilgenbauer, A Schnaiter, P Paschka, T Zenz, M Rossi, K Döhner, ... Blood, The Journal of the American Society of Hematology 123 (21), 3247-3254, 2014 | 668 | 2014 |
| Recurrent mutations refine prognosis in chronic lymphocytic leukemia P Baliakas, A Hadzidimitriou, LA Sutton, D Rossi, E Minga, N Villamor, ... Leukemia 29 (2), 329-336, 2015 | 401 | 2015 |
| Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open … O Al-Sawaf, C Zhang, M Tandon, A Sinha, AM Fink, S Robrecht, ... The Lancet Oncology 21 (9), 1188-1200, 2020 | 357 | 2020 |
| Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3 … AD Zelenetz, JC Barrientos, JR Brown, B Coiffier, J Delgado, M Egyed, ... The Lancet Oncology 18 (3), 297-311, 2017 | 276 | 2017 |
| Final results of a randomized, phase III study of rituximab with or without idelalisib followed by open-label idelalisib in patients with relapsed chronic lymphocytic leukemia JP Sharman, SE Coutre, RR Furman, BD Cheson, JM Pagel, P Hillmen, ... Journal of Clinical Oncology 37 (16), 1391-1402, 2019 | 248 | 2019 |
| ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia—update on methodological approaches and results interpretation J Malcikova, E Tausch, D Rossi, LA Sutton, T Soussi, T Zenz, AP Kater, ... Leukemia 32 (5), 1070-1080, 2018 | 240 | 2018 |
| Venetoclax resistance and acquired BCL2 mutations in chronic lymphocytic leukemia E Tausch, W Close, A Dolnik, J Bloehdorn, B Chyla, L Bullinger, H Döhner, ... Haematologica 104 (9), e434, 2019 | 228 | 2019 |
| First-line venetoclax combinations in chronic lymphocytic leukemia B Eichhorst, CU Niemann, AP Kater, M Fürstenau, J Von Tresckow, ... New England Journal of Medicine 388 (19), 1739-1754, 2023 | 186 | 2023 |
| Complex karyotypes and KRAS and POT1 mutations impact outcome in CLL after chlorambucil-based chemotherapy or chemoimmunotherapy CD Herling, M Klaumünzer, CK Rocha, J Altmüller, H Thiele, J Bahlo, ... Blood, The Journal of the American Society of Hematology 128 (3), 395-404, 2016 | 149 | 2016 |
| Venetoclax and obinutuzumab in chronic lymphocytic leukemia K Fischer, O Al-Sawaf, AM Fink, M Dixon, J Bahlo, S Warburton, TJ Kipps, ... Blood, The Journal of the American Society of Hematology 129 (19), 2702-2705, 2017 | 139 | 2017 |
| Minimal residual disease dynamics after venetoclax-obinutuzumab treatment: extended off-treatment follow-up from the randomized CLL14 study O Al-Sawaf, C Zhang, T Lu, MZ Liao, A Panchal, S Robrecht, T Ching, ... Journal of Clinical Oncology 39 (36), 4049-4060, 2021 | 135 | 2021 |
| Prognostic and predictive impact of genetic markers in patients with CLL treated with obinutuzumab and venetoclax E Tausch, C Schneider, S Robrecht, C Zhang, A Dolnik, J Bloehdorn, ... Blood, The Journal of the American Society of Hematology 135 (26), 2402-2412, 2020 | 134 | 2020 |
| Higher-order connections between stereotyped subsets: implications for improved patient classification in CLL A Agathangelidis, A Chatzidimitriou, K Gemenetzi, V Giudicelli, ... Blood, The Journal of the American Society of Hematology 137 (10), 1365-1376, 2021 | 128 | 2021 |
| Bendamustine followed by obinutuzumab and venetoclax in chronic lymphocytic leukaemia (CLL2-BAG): primary endpoint analysis of a multicentre, open-label, phase 2 trial P Cramer, J von Tresckow, J Bahlo, S Robrecht, P Langerbeins, ... The Lancet Oncology 19 (9), 1215-1228, 2018 | 122 | 2018 |
| Second Interim Analysis of a Phase 3 Study of Idelalisib (ZYDELIG®) Plus Rituximab (R) for Relapsed Chronic Lymphocytic Leukemia (CLL): Efficacy Analysis in … JP Sharman, SE Coutre, RR Furman, BD Cheson, JM Pagel, P Hillmen, ... Blood, The Journal of the American Society of Hematology 124 (21), 330-330, 2014 | 113 | 2014 |
| Molecular map of chronic lymphocytic leukemia and its impact on outcome BA Knisbacher, Z Lin, CK Hahn, F Nadeu, M Duran-Ferrer, KE Stevenson, ... Nature genetics 54 (11), 1664-1674, 2022 | 110 | 2022 |
| Richter transformation in chronic lymphocytic leukemia (CLL)—a pooled analysis of German CLL Study Group (GCLLSG) front line treatment trials O Al-Sawaf, S Robrecht, J Bahlo, AM Fink, P Cramer, J v Tresckow, ... Leukemia 35 (1), 169-176, 2021 | 99 | 2021 |